Where Can I Get a Single Measles Vaccine?

Standalone measles vaccines are no longer available through routine healthcare channels in most high-income countries, including the United States and the United Kingdom. In the U.S., Merck discontinued Attenuvax, the only licensed single-antigen measles vaccine, in 2009, and no replacement has been approved since. The combined measles-mumps-rubella (MMR) vaccine is now the only measles-containing option available through standard medical providers in most Western countries. That leaves parents and adults who specifically want a measles-only shot in a frustrating position, and the reasons behind both the demand and the limited supply are worth understanding.

Why Single Measles Vaccines Disappeared

The disappearance was driven by economics and logistics, not safety problems. Once MMR became the standard recommendation in the 1970s and 1980s, demand for single-antigen measles vaccines steadily dropped. Manufacturers had little financial incentive to keep producing three separate vaccines when a single combination shot covered all three diseases in one visit. By the time Merck pulled Attenuvax from the market, the vast majority of doses administered worldwide were already MMR. The same thing happened with standalone mumps and rubella vaccines around the same time.

This matters because it means the unavailability is not a medical judgment that single vaccines are unsafe. They worked perfectly well. The market simply moved on. When only a handful of parents request a product that requires its own manufacturing line, quality testing, and regulatory upkeep, the economics don’t hold up for pharmaceutical companies.

The Wakefield Controversy and the Surge in Demand

The irony is that demand for single measles vaccines surged just as supply was drying up. In 1998, Andrew Wakefield published a now-retracted study suggesting a link between the MMR vaccine and autism. The study was later found to be fraudulent, and Wakefield lost his medical license. But the damage to public confidence lingered for years, particularly in the UK. Media coverage of Wakefield’s claims caused widespread alarm among parents of young children and contributed to a significant decline in MMR uptake.¹

Research into how parents actually made their decisions in the decade after the controversy revealed something interesting. Parents who opted for single vaccines didn’t necessarily buy into Wakefield’s autism claim. Many of them rejected the study outright but still felt that not all three components of MMR were justified by disease severity. Their reasoning was less about “immune overload” and more about questioning whether their child really needed protection against mumps or rubella at that age.²

That distinction matters. The “immune overload” concern, the idea that giving three live viruses at once overwhelms a child’s immune system, has been studied extensively and is not supported by evidence. But the separate concern that not every component of a combination vaccine feels equally necessary to a given parent is a values question, not a scientific one, and it continues to drive demand for standalone options even now.

Where Single Measles Vaccines Still Exist

If you are determined to find a standalone measles vaccine, your options depend heavily on where you live. In the United States, there is currently no FDA-licensed single measles vaccine available. No pharmacy, pediatrician’s office, or public health clinic can offer one through normal channels. The same is true across most of the European Union.

In the UK, a small number of private clinics have historically stocked imported single-antigen measles vaccines, but availability has become increasingly unreliable. These clinics typically source their vaccines from manufacturers in countries where monovalent measles vaccines are still produced for national immunization programs, such as India. The quality of these imported products can be perfectly adequate since they are manufactured to World Health Organization standards for use in large-scale vaccination campaigns. However, private clinics offering single vaccines tend to charge substantially more per dose, and finding one with current stock can require significant effort.

Some countries in South Asia, sub-Saharan Africa, and other regions with large childhood immunization programs still use monovalent measles vaccine as part of their routine schedules, sometimes giving it at nine months of age before following up with MMR later. A study comparing these two approaches found that children who received a single measles dose at nine months had a seroconversion rate of about 70%, while those revaccinated with MMR at fifteen months reached about 90%.³ That gap underscores why a single early dose is often considered a stopgap measure in regions where measles exposure risk is high before the standard MMR age, not a replacement for the combined vaccine.

Why Health Authorities Recommend MMR Over Splitting

Every major health authority, from the CDC and the NHS to the WHO, recommends the combined MMR vaccine over separate single-antigen shots. Their reasoning goes beyond convenience, though convenience is a real factor.

The biggest concern with splitting vaccines into individual components is the gap it creates. If you give measles at one visit, mumps at another, and rubella at a third, you have tripled the number of appointments needed and left the child unprotected against two diseases for weeks or months between doses. Research on alternative immunization schedules confirms that these approaches increase the total time a child spends unvaccinated and demand more from both families and healthcare providers.⁴

The dropout problem is real and well-documented. Even in settings where split schedules are technically available, many families don’t complete the full course. Life gets in the way: a scheduling conflict, a minor illness that pushes back the next appointment, a move to a new area. Each additional required visit increases the chance that a child falls through the cracks. Early research on childhood vaccination programs showed that requiring more visits led to substantially higher dropout rates, reducing overall coverage in the population.⁵ The same principle applies when parents try to space out measles, mumps, and rubella into separate appointments.

From a population standpoint, this is not a small problem. Measles is extraordinarily contagious. It requires vaccination coverage above roughly 95% to maintain herd immunity. When uptake drops even a few percentage points because families start but don’t finish a more complicated schedule, outbreaks become possible in communities that were previously protected.

The Allergy Question

One of the more common medical reasons people ask about alternatives to MMR is allergy. The MMR vaccine is produced using fibroblast cell cultures and contains trace amounts of egg protein and, in some formulations, gelatin as a stabilizer. Parents of children with egg allergy or gelatin allergy sometimes worry that the combined vaccine poses a special risk and wonder whether a single measles vaccine might be safer.

For egg allergy specifically, the evidence is reassuring. A recent study performed MMR vaccinations in children with confirmed egg allergy, including children who had previously experienced anaphylaxis after eating eggs. Out of 39 vaccinations, none resulted in a systemic allergic reaction. One child developed a mild rash that resolved with a single dose of antihistamine.⁶ This aligns with broader guidance: egg allergy, even severe egg allergy, is not a contraindication to MMR vaccination. The amount of egg protein in the vaccine is extremely small, and the manufacturing process differs from that of flu vaccines, which contain more egg-derived material.

Gelatin allergy is a slightly different story. Some MMR formulations contain hydrolyzed gelatin, and children with a confirmed gelatin allergy do need more careful management. Research suggests that a gelatin-free vaccine formulation is preferable for these patients. When a gelatin-free option isn’t available, an intradermal skin test with the vaccine itself before administering the full dose is recommended.⁷ In practice, gelatin allergy is uncommon, and allergists can manage the situation without needing a different vaccine product altogether. Seeking out a single measles vaccine for allergy reasons is rarely necessary.

MMRV Versus MMR and What It Means for Your Decision

If your concern is about combining too many antigens in one shot, you should know that there is actually a four-component vaccine on the market: MMRV, which adds varicella (chickenpox) to the standard MMR. This vaccine has drawn its own scrutiny, particularly around febrile seizures in young children.

Population-level data shows that the risk of seizures in the 7 to 10 days after vaccination was about twice as high with MMRV compared to giving MMR and varicella as separate injections at the same visit. In absolute terms, the excess risk worked out to roughly 3.5 additional seizures per 10,000 doses.⁸ A separate study found that the odds of febrile convulsions in the main risk window were roughly four times higher with MMRV than with MMR alone.⁹

These febrile seizures, while frightening for parents, are typically brief and do not cause lasting harm. Still, the increased risk with MMRV is the reason the CDC recommends that for the first dose in children aged 12 to 47 months, parents and providers discuss whether to use MMRV or give MMR and varicella separately. For the second dose, typically given at age 4 to 6, MMRV is generally preferred because the febrile seizure risk is much lower at that age.

The practical takeaway: if your worry is specifically about “too many vaccines at once,” you have more control than you might think without needing a single measles vaccine. You can opt for MMR plus a separate varicella shot rather than MMRV, and that choice is well supported by the evidence. It gets you the same protection with a slightly lower seizure risk for the first dose.

What to Do If You Still Want to Avoid MMR

If, after weighing all of this, you remain set on avoiding the combined MMR vaccine, here is what the practical landscape looks like. In the United States, you have no legal path to a standalone measles vaccine through a licensed provider. Some naturopathic or integrative medicine clinics have claimed to offer imported single vaccines, but these products are not FDA-approved and their quality, storage, and handling cannot be verified through normal regulatory channels. Using an unregulated product introduces risks that are genuinely harder to quantify than the well-studied safety profile of MMR.

In the UK, your best bet is to search for private travel vaccination clinics that stock imported monovalent vaccines. Availability fluctuates, and you should expect to pay out of pocket since the NHS does not cover single-antigen measles vaccines. If you go this route, ask the clinic about the manufacturer, the vaccine’s country of origin, and its cold-chain handling. A reputable clinic will answer these questions openly.

In either country, if the reason you are avoiding MMR is a specific medical concern, such as an allergy, an immune deficiency, or a previous adverse reaction, the right first step is a conversation with an allergist or immunologist rather than a search for alternative products. Most of the medical situations that make parents hesitant about MMR turn out to be manageable with the standard vaccine under appropriate supervision.

Measles Itself and Why Timing Matters

It is easy to lose sight of measles the disease when the conversation focuses entirely on vaccine formulations. Measles is not a benign childhood rash. Before widespread vaccination, measles killed hundreds of children each year in the United States and hospitalized thousands more. Globally, it remains one of the leading causes of death among young children. The virus is so contagious that if one person has it, up to 90% of unvaccinated people in close contact will also become infected.

Every month a child goes unvaccinated while parents search for a single vaccine is a month of real vulnerability, especially during outbreaks. Measles outbreaks have occurred in recent years in communities with lower-than-average vaccination rates in both the U.S. and UK, often spreading rapidly through schools and childcare settings. The children caught up in these outbreaks are overwhelmingly those who were either unvaccinated or incompletely vaccinated.

The uncomfortable truth is that for many parents seeking single vaccines, the search itself becomes the risk. Months pass while waiting for a clinic to restock, or while spacing out separate doses, and during that window the child has no protection at all. From a risk-benefit standpoint, the known and well-characterized safety profile of MMR is far more favorable than the unknown risk of remaining unvaccinated during a prolonged search for a product that may not materialize.

Adults Who Need Measles Protection

This question doesn’t only come from parents. Adults born after 1957 who never received MMR, who received only one dose, or who lack documented immunity sometimes need measles vaccination, particularly before international travel, when starting healthcare employment, or during outbreaks. For adults, the same constraints apply: no standalone measles vaccine is available in the U.S. or most of Europe, so MMR is the recommended option.

Adults sometimes worry about receiving a vaccine “designed for children,” but MMR is licensed for all ages and is routinely given to adults. Side effects in adults are generally mild, with the most common being soreness at the injection site and occasionally a low-grade fever or mild rash about a week after vaccination. Serious adverse events are rare across all age groups.

If you are an adult who already had mumps or rubella, or who already has documented immunity to those diseases, receiving MMR will not cause any harm. Getting an additional dose of a component you’re already immune to simply means your immune system recognizes it and mounts a quick, uneventful response. There is no medical reason to seek out a single measles vaccine to avoid “redundant” mumps or rubella antigens, because that redundancy is immunologically harmless.

The Private Market in Other Countries

If you travel frequently or live part of the year in another country, you may encounter single measles vaccines in places where they are still part of the national immunization program. India, for example, manufactures and distributes monovalent measles vaccine through its Universal Immunisation Programme, and it can sometimes be obtained through private hospitals there. Some countries in Southeast Asia and Africa similarly maintain standalone measles vaccine supplies.

Receiving a vaccine abroad and bringing documentation back to your home country is legally straightforward in most cases. Your pediatrician or family doctor can record a foreign-administered vaccine in your or your child’s immunization record. However, the logistics of traveling to another country specifically to obtain a single measles vaccine are obviously impractical for most families and introduce their own health risks, particularly if measles is circulating in the destination country.

For families already planning travel to a country where monovalent measles vaccine is available, it could be worth asking a local physician about it. Just be aware that the vaccine may be formulated differently from what you are used to, and storage conditions during transport back home can compromise the product. Live vaccines like measles are sensitive to temperature, and a broken cold chain renders the dose useless without any visible sign of degradation.